Investor Presentation First Nine Months of 2022
90
Investor presentation First nine months of 2022
Novo Nordisk is expanding into other serious chronic diseases
Serious chronic diseases are often associated with diabetes and obesity
New therapeutic areas represent patient populations with high
unmet medical needs
Novo NordiskⓇ
Estimated patients
AD
Patients with AD live from 2 to 20
years from dementia onset
AD
~85 million
Available treatments
No approved disease modifying
medical treatments
70% of people with diabetes die
from atherosclerotic CVD
Estimated patients
Number of related deaths
CVD
40% of people hospitalised for
heart failure have diabetes
CVD
~420 million
-20 million annually
Estimated patients
NASH
80% of people with NASH live with
obesity and 35% have diabetes
NASH
~15-40 million¹
CKD
•
40% of people with diabetes have
diabetic nephropathy and 50% have
obesity
CKD
~200 million
Diagnosis rate
-20%2
-20%
1 Internal forecast comprising the USA, Europe and Japan; 2 Diagnosis rate is considered a major uncertainty to the forecast
CVD: Cardiovascular disease; NASH: Non-alcoholic Steatohepatitis; CKD: Chronic kidney disease; AD: Alzheimer's Disease
Sources: Alzheimer's Association report: 2020 Alzheimer's disease facts and figures, 2020 (16:391-460), Diabetes Care 2005 Jan; 28(1): 164-176; Abera SF et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015, 2017;
Heart Disease and Stroke Statistics, American Heart Association, 2017; Williams CD et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy, 2011;
Addressing the global burden of chronic kidney disease through clinical and translational research, 2014View entire presentation